Amvuttra

Product

Heard on podcasts recently

Amvuttra is a prescription medicine developed by Alnylam Pharmaceuticals for treating transthyretin-mediated amyloidosis, including cardiomyopathy associated with ATTR-CM.

Discussed inMarkets100%

Rank this week

—
Not in this week’s list

Share of the conversation

—

Reach this week

—

Tone this week

—

Not enough signal yet (fewer than 3 episodes scored).

Share of the conversation

Mentions of Amvuttra per 1,000 mentions of anything, 7-day rolling, all podcasts.

0.0‰0.02‰0.04‰0.06‰Aug 24Sep 15Oct 8Oct 30Nov 21
Show the data
DayShare (7-day)Mentions
Oct 300.01‰1
Nov 130.03‰4

Who is saying what about Amvuttra

Verified quotes from the last 90 days: who made the most claims, and which way they leaned.

Discussed alongside

Names that come up in the same conversations as Amvuttra.

See 1 more with Pro

Embed this

Paste this on your site to show Amvuttra's current trend:

<iframe src="https://podlume.ai/embed/e/amvuttra" width="360" height="220" style="border:0" loading="lazy" title="Amvuttra on PodLume Trends"></iframe>